Sophiris Bio, Inc.
SPHS
SPHS was delisted on the 11th of March, 2020.
34 hedge funds and large institutions have $3.43M invested in Sophiris Bio, Inc. in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 6 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
6% more funds holding
Funds holding: 32 → 34 (+2)
21% less capital invested
Capital invested by funds: $4.35M → $3.43M (-$920K)
23% less call options, than puts
Call options by funds: $181K | Put options by funds: $235K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$235K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$44.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$42K |
| 4 |
Squarepoint
New York
|
+$29.9K |
| 5 |
Bank of New York Mellon
New York
|
+$28.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$295K |
| 2 |
Millennium Management
New York
|
-$206K |
| 3 |
Goldman Sachs
New York
|
-$125K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$121K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$55K |
SPHS Hedge Fund Activity: Q1 2018 in Review
34 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q1 2018, worth a combined $3.43M — down 21% from $4.35M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SPHS positions and 6 closed out — a net gain of 2 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $235K. The largest seller was Virtu Financial, cutting an estimated $295K.
- 34 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q1 2018, up from 32 in Q4 2017.
- Funds reported $3.43M of Sophiris Bio, Inc. stock for Q1 2018, down 21% quarter-over-quarter.
- 8 funds opened new Sophiris Bio, Inc. positions in Q1 2018 and 6 closed out, a net change of +2 holders.
- The largest Sophiris Bio, Inc. buyer in Q1 2018 was Vanguard Group, an estimated $235K added.
- The largest Sophiris Bio, Inc. seller in Q1 2018 was Virtu Financial, an estimated $295K sold.
Based on aggregated 13F filings for Q1 2018.